IMNNImunon, Inc.

Nasdaq imunon.com


$ 1.53 $ 0.22 (17.19 %)    

Wednesday, 08-May-2024 15:59:25 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 1.5
$ 1.30
$ 0.00 x 0
$ 0.00 x 0
$ 1.30 - $ 1.53
$ 0.48 - $ 2.00
85,356
na
13.57M
$ 1.44
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-28-2024 12-31-2023 10-K
2 11-14-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-30-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-31-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-14-2021 03-31-2021 10-Q
13 03-19-2021 12-31-2020 10-K
14 11-16-2020 09-30-2020 10-Q
15 08-14-2020 06-30-2020 10-Q
16 05-15-2020 03-31-2020 10-Q
17 03-25-2020 12-31-2019 10-K
18 11-14-2019 09-30-2019 10-Q
19 08-14-2019 06-30-2019 10-Q
20 05-15-2019 03-31-2019 10-Q
21 03-29-2019 12-31-2018 10-K
22 11-14-2018 09-30-2018 10-Q
23 08-14-2018 06-30-2018 10-Q
24 05-11-2018 03-31-2018 10-Q
25 03-27-2018 12-31-2017 10-K
26 11-14-2017 09-30-2017 10-Q
27 08-14-2017 06-30-2017 10-Q
28 05-12-2017 03-31-2017 10-Q
29 03-24-2017 12-31-2016 10-K
30 11-10-2016 09-30-2016 10-Q
31 08-15-2016 06-30-2016 10-Q
32 05-16-2016 03-31-2016 10-Q
33 03-30-2016 12-31-2015 10-K
34 11-05-2015 09-30-2015 10-Q
35 08-10-2015 06-30-2015 10-Q
36 05-11-2015 03-31-2015 10-Q
37 03-12-2015 12-31-2014 10-K
38 11-10-2014 09-30-2014 10-Q
39 08-07-2014 06-30-2014 10-Q
40 05-08-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 imunon-appoints-stacy-r-lindborg-as-president-and-ceo-effective-may-13-2024

Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experienc...

 imunon-reports-compliance-with-nasdaq-listing-requirements

IMUNON, Inc. (NASDAQ:IMNN) ("IMUNON" or the "Company"), a clinical-stage drug-development company focused on de...

 imunon-files-formrw-co-determined-not-to-pursue-the-public-offering-to-which-the-registration-statement-relates-the-registration-statement-has-not-been-declared-effective-by-the-sec-and-the-registrant-confirms-that-no-securities-have-been-sold-pursuant-to-the-registration-statement

- SEC Filing

 hc-wainwright--co-maintains-buy-on-imunon-raises-price-target-to-13

HC Wainwright & Co. analyst Emily Bodnar maintains Imunon (NASDAQ:IMNN) with a Buy and raises the price target from $12 ...

 imunon-q4-eps-052-beats-230-estimate

Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(2.30) by 77....

 imunon-fy2023-eps-216-beats-230-estimate

Imunon (NASDAQ:IMNN) reported quarterly losses of $(2.16) per share which beat the analyst consensus estimate of $(2.30) by 6.0...

 earnings-scheduled-for-march-28-2024

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...

 preview-imunons-earnings
Preview: Imunon's Earnings
03/27/2024 17:01:43

 hc-wainwright--co-reiterates-buy-on-imunon-maintains-12-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Imunon (NASDAQ:IMNN) with a Buy and maintains $12 price target.

 imunon-files-ind-application-to-begin-human-testing-of-imnn-101-expects-enrollment-in-phase-1-proof-of-concept-study-of-dna-based-vaccine-technology-to-begin-in-q2

Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2 The application fo...

 independent-lab-announces-results-from-imunons-imnn-101-live-virus-challenge-against-sars-cov-2-variant-xbb15

Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Va...

 why-bumble-shares-are-trading-lower-by-12-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION